The Functional Cancer Genomics group directed by Prof. J.P. Theurillat at the Institute of Oncology Research in Bellinzona, Switzerland (http://www.ior.iosi.ch) is seeking a part- or full-time Technician in cancer research.
The successful candidate will work as part of an international team that is dedicated to understanding how new driver alterations culled from cancer genome characterization studies promote tumorigenesis, and how gathered insights can be exploited to develop precision medicines. The position offers excellent scientific opportunities in a highly stimulating and interdisciplinary environment involving close interactions between medical and basic scientists. Investigations range from projects related to:
- Patient-derived xenograft (PDX) mouse models to study the biology of prostate cancer
- Determining anti-tumor activity of novel drug-like compounds in vivo
- Working experience with mouse models (tumor xenograft models or geneticallyengineered mice): breeding setup and grafting of tumors, drug application, small surgery (castration), tissue preservation
- Working experience in cell culture models and basic molecular biology desirable
- MSc or PhD in biology
The position is located at the Institute of Oncology Research, a leading institution in basic and translational cancer research in Southern Switzerland with state-of-the-art core facilities and competitive salaries. The highly collaborative lab has ongoing projects with groups at Harvard, MIT and ETHZ, among others.
Starting date: fall 2020
Applicants should submit curriculum vitae, cover letter and contact info for 2 references to
firstname.lastname@example.org with reference JPT_Technician 2020.
For additional inquiry regarding this job please contact Prof. Jean-Philippe Theurillat via email:
Selected recent publications:
- Janouskova H, et al. Opposing effects of cancer type-specific SPOP mutations on BET protein degradation and sensitivity to BET inhibitors. Nat Med 2017. PMID: 28805821
- Groner A, et al. TRIM24 is an oncogenic transcriptional activator in prostate cancer. Cancer Cell 2016 PMID: 27238081
- Theurillat JP, et al. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science 2014 PMID: 25278611
- Whittaker SR, et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov 2013 PMID: 23288408
- Barbieri CE1, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012 PMID: 22610119
- Theurillat JP, et al. URI is an oncogene amplified in ovarian cancer cells and is required for their survival. Cancer Cell 2011 PMID: 21397856